Friday, June 3, 2022, Chicago, Illinois, 11:45 AM – 12:45 PM Central Time (12:45 PM – 1:45 PM Eastern Time)

Lunch with the Investigators: Acute Myeloid Leukemia and Myelodysplastic Syndromes

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
11:30 AM – 11:45 AM — Registration
11:45 AM – 12:45 PM — Lunch Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Michael R Savona, MD
Section Head, Hematology, Cellular Therapy and Stem Cell Transplantation
Beverly and George Rawlings Directorship in Hematology Research
Professor of Medicine and Cancer Biology
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee


Eunice S Wang, MD
Chief, Leukemia Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York



Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Novartis.
Program Schedule — Central Time
11:30 AM – 11:45 AM — Registration
11:45 AM – 12:45 PM — Educational Lunch Meeting

MODULE 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML)

  • Factors in the selection of initial therapy for patients with newly diagnosed AML (eg, age, performance status, medical history, cytogenetic risk profile)
  • Key efficacy and safety data with venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML ineligible for intensive induction chemotherapy
  • Preliminary findings with and ongoing investigations of venetoclax for younger, fit patients with newly diagnosed AML
  • Principal findings with and current clinical role of CPX-351 for previously untreated secondary AML
  • Early results with and ongoing evaluation of CPX-351 alone or combined with other agents for primary AML
  • Available data with and ongoing evaluation of other promising agents and strategies for AML (eg, magrolimab, sabatolimab, menin inhibitors)

MODULE 2: Therapy for Patients with AML and Targetable Mutations

  • Key outcomes from Phase III trials comparing gilteritinib to salvage chemotherapy for patients with relapsed/refractory AML with a FLT3 mutation
  • Available data with gilteritinib combined with standard induction or consolidation chemotherapy for newly diagnosed AML; ongoing investigations of gilteritinib
  • Pharmacologic similarities and differences between available (eg, midostaurin, gilteritinib) and investigational (eg, quizartinib, crenolanib) FLT3 inhibitors in AML
  • Emerging results from the Phase III QuANTUM-First study showing an overall survival advantage with quizartinib added to chemotherapy compared to chemotherapy alone for patients with newly diagnosed AML with a FLT3-ITD mutation
  • Key data from the Phase III AGILE study of ivosidenib/azacitidine versus azacitidine alone as front-line therapy for AML with an IDH1 mutation
  • Early-phase data from other studies attempting to incorporate ivosidenib or enasidenib as a component of up-front therapy for AML with an IDH1 or IDH2 mutation
  • Efficacy of venetoclax-based therapy for patients with AML with FLT3 or IDH1/2 mutations; ongoing research assessing venetoclax in combination with targeted therapy

MODULE 3: Current and Future Management of Myelodysplastic Syndromes (MDS)

  • Key clinical and biologic factors in the selection and sequencing of currently available therapies for patients with low-, intermediate- and high-risk MDS
  • Key data supporting the recent FDA breakthrough therapy designation for venetoclax in combination with azacitidine for treatment-naïve intermediate-, high- or very high-risk MDS; current nonresearch role and ongoing Phase III evaluation
  • Biologic rationale for targeting CD47 in MDS; available efficacy and safety findings with magrolimab in combination with azacitidine as first-line therapy for higher-risk disease
  • Rationale for targeting TIM-3 in patients with MDS; mechanism of action of sabatolimab and published results in combination with a hypomethylating agent
  • Early activity and safety data with and ongoing evaluation of other promising novel approaches for MDS

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the importance of patient age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for various presentations of AML.
  • Appreciate the FDA approval of venetoclax with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are 75 years or older or not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Reflect on published research with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Understand the mechanisms of action of, available data with and current and emerging role for available IDH1/2 inhibitors for newly diagnosed or relapsed/refractory AML with an IDH1 or IDH2 mutation.
  • Assess the FDA-approved indication for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
  • Formulate a treatment algorithm for lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
  • Develop an understanding of the biologic rationale for and available data with emerging novel combination regimens for higher-risk MDS in order to prepare for their potential availability in routine practice.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr DiNardoAdvisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, CleaveTherapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs. Dr SavonaAdvisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, CTI BioPharma Corp, Geron, Karyopharm Therapeutics, Novartis, Ryvu Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements and Ownership Interest: Karyopharm Therapeutics, Ryvu Therapeutics; Contracted Research: ALX Oncology, Incyte Corporation, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Sierra Oncology, TG Therapeutics Inc. Dr WangAdvisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.